Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Biomarkers

Topic: Brain proteins, microglia and lab models

Plain-language summary

Background and objectives The objective of this study was to determine the relationship between plasma β-amyloid (Aβ), specifically the ratio of 2 Aβ peptides (the Aβ 42 /Aβ 40 ratio, which correlates with increased accumulation of Aβ in the CNS), and late-onset epilepsy (LOE). Methods We used Medicare fee-for-service claims codes from 1991 to 2018 to identify cases of LOE among 1,424 Black and White men and women enrolled in the Atherosclerosis Risk in Communities (ARIC) study cohort. The Aβ 42 /Aβ 40 ratio was calculated from plasma samples collected from ARIC participants in 1993-1995 (age 50-71 years) and 2011-2013 (age 67-90 years). We used survival analysis accounting for the competing risk of death to determine the relationship between late-life plasma Aβ 42 /Aβ 40 , and its change from midlife to late life, and the subsequent development of epilepsy. We adjusted for demographics, the apolipoprotein e4 genotype, and comorbidities, including stroke, dementia, and head injury. A low plasma ratio of 2 Aβ peptides, the Aβ 42 /Aβ 40 ratio, correlates with low CSF Aβ 42 /Aβ 40 and with increased accumulation of Aβ in the CNS. Results Decrease in plasma Aβ 42 /Aβ 40 ratio from midlife to late life, but not an isolated measurement of Aβ 42 /Aβ 40 , was associated with development of epilepsy in later life. For every 50% reduction in Aβ 42 /Aβ 40 , there was a 2-fold increase in risk of epilepsy (adjusted subhazard ratio 2.30, 95% CI 1.27-4.17). Discussion A reduction in plasma Aβ 42 /Aβ 40 is associated with an increased risk of subsequent epilepsy. Our observations provide a further validation of the link between Aβ, hyperexcitable states, and LOE.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Johnson, E. L., Sullivan, K. J., Schneider, A. L. C., Simino, J., Mosley, T. H., Kucharska-Newton, A., et al. (2023). Association of Plasma Aβ42/Aβ40 Ratio and Late-Onset Epilepsy: Results From the Atherosclerosis Risk in Communities Study. Neurology. https://doi.org/10.1212/wnl.0000000000207635

Vancouver

Johnson EL, Sullivan KJ, Schneider ALC, Simino J, Mosley TH, Kucharska-Newton A, et al. Association of Plasma Aβ42/Aβ40 Ratio and Late-Onset Epilepsy: Results From the Atherosclerosis Risk in Communities Study. Neurology. 2023. doi:10.1212/wnl.0000000000207635. PMID: 37541842.

BibTeX

@article{johnson2023-37541842,
  author  = {Johnson, E. L. and Sullivan, K. J. and Schneider, A. L. C. and Simino, J. and Mosley, T. H. and Kucharska-Newton, A. and Knopman, D. S. and Gottesman, R. F.},
  title   = {{Association of Plasma Aβ42/Aβ40 Ratio and Late-Onset Epilepsy: Results From the Atherosclerosis Risk in Communities Study}},
  journal = {Neurology},
  year    = {2023},
  doi     = {10.1212/wnl.0000000000207635},
  pmid    = {37541842},
  url     = {https://doi.org/10.1212/wnl.0000000000207635}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Study details

How this study scored 47/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record left out, no data; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here left out, no data; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 2 of 2; Free to read 0 of 2. 27 of the 58 points it could be judged on, which is 47 of 100. Total 47 of 100.27 of the 58 points we could judge = 47 of 100

Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 27 of the 58 points we could judge it on, which is 47 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Neurology)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2023 — within 6 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here — / 6 Not yet checked against this library's citation graph — left out of this score
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 37541842)
Free to read 0 / 2 Behind a paywall — scores zero
Points 27 / 58 Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 27 of the 58 points we could judge it on is 47 out of 100.
Total 47 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Biomarkers from nearby years

Also tagged “late-onset-epilepsy”

2 studies in the library carry the topic tag “late-onset-epilepsy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →